Similar articles

• Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.

  Bihl F, Mosam A, Henry LN, Chisholm JV 3rd, Dollard S, Gumbi P, Cassol E, Page T, Mueller N, Kiepiela P, Martin JN, Coovadia HM, Scadden DT, Brander C. Bihl F, et al. AIDS. 2007 Jun 19;21(10):1245-52. doi: 10.1097/QAD.0b013e328182df03. AIDS. 2007. PMID: 17545700 Clinical Trial.
• Fatal Kaposi's sarcoma-associated immune reconstitution following highly active antiretroviral therapy.

  Kawsar M. Kawsar M. Int J STD AIDS. 2005 Aug;16(8):582-3; author reply 583. doi: 10.1258/0956462054679278. Int J STD AIDS. 2005. PMID: 16105195 No abstract available.
• [Diagnosis and treatment of HIV-related Kaposi's sarcoma].

  Reyners AK, Sprenger HG, Suurmeijer AJ, van der Graaf WT. Reyners AK, et al. Ned Tijdschr Geneeskd. 2006 Mar 18;150(11):589-93. Ned Tijdschr Geneeskd. 2006. PMID: 16610494 Dutch.
• Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment.

  Dittmer DP, Vahrson W, Staudt M, Hilscher C, Fakhari FD. Dittmer DP, et al. AIDS Rev. 2005 Jan-Mar;7(1):56-61. AIDS Rev. 2005. PMID: 15875661 Review.
• Treatment of Kaposi's sarcoma.

  Von Roenn JH, Cianfrocca M. Von Roenn JH, et al. Cancer Treat Res. 2001;104:127-48. Cancer Treat Res. 2001. PMID: 11191125 Review. No abstract available.